Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.56 |
| ▸ | HTR3B | O95264 | 2/20 | 0.56 |
| ▸ | HTR3A | P46098 | 2/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9309714 | 0.98 | BPTF (0.96) | BPTFCYP1A2ALDH1A1HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL4818062 | 0.98 | BPTF (0.96) | BPTFCYP1A2ALDH1A1HTR3EHTR3B | |
| SCHEMBL5238778 | 0.93 | BPTF (0.87) | BPTFCYP1A2ALDH1A1HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL9219094 | 0.92 | BPTF (0.84) | BPTFCYP1A2ALDH1A1HTR3EHTR3B | |
| SCHEMBL6354020 | 0.92 | BPTF (0.84) | BPTFCYP1A2ALDH1A1HTR3EHTR3B | |
| SCHEMBL6360151 | 0.89 | BPTF (0.80) | BPTFCYP1A2ALDH1A1HTR3EHTR3B | |
| Fumaric Acid SCHEMBL27601353 | 0.86 | BPTF (0.74) | BPTFCYP1A2ALDH1A1HTR3EHTR3B | |
| SCHEMBL9990416 | 0.82 | CYP1A2 (0.88) | BPTFCYP1A2ALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL421732 | 0.82 | CYP1A2 (0.96) | BPTFCYP1A2ALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL29845748 | 0.82 | CYP1A2 (0.96) | BPTFCYP1A2ALDH1A1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4312456-B2 | — | — | 2009-08-12 | — | — | JP | claimed |
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | OLSEN GUNNAR M | 2007-11-15 | — | — | US | claimed |
| EP-1757600-A2 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NeuroSearch A/S (DK) | 2007-02-28 | — | — | EP | claimed |
| CN-1635877-A | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH AS (DK) | 2005-07-06 | — | — | CN | claimed |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | ANIONA APS (DK) | 2004-05-13 | — | — | US | claimed |
| JP-2004510813-A | — | — | 2004-04-08 | — | — | JP | claimed |
| EP-1358177-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NeuroSearch A/S (DK) | 2003-11-05 | — | — | EP | claimed |
| WO-2002030405-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | WO | claimed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220185796-A1 | SMALL MOLECULE MODULATORS OF PANK | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2022-06-16 | — | — | US | disclosed |
| US-20220185796-A1 | SMALL MOLECULE MODULATORS OF PANK | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2022-06-16 | — | — | US | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2020198526-A2 | SMALL MOLECULE MODULATORS OF PANK | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2020-10-01 | — | — | WO | disclosed |
| EP-0055583-B1 | ANTIHYPERTENSIVES | Pfizer Limited (GB) | 1985-08-28 | — | — | EP | disclosed |
| US-4483859-A | 4-Amino-6, 7-dimethoxy-2-(4-heteroaryl-piperazino) quinazoline _antihypertensives | PFIZER INC. (US) | 1984-11-20 | — | — | US | disclosed |
| US-4483857-A | 4-Amino-6,7-dimethoxy-2-(4-heteroaryl-piperazino)quinazoline antihypertensives | PFIZER INC. (US) | 1984-11-20 | — | — | US | disclosed |
| US-4435401-A | 4-Amino-6,7-dimethoxy-2-(4-heteroaryl-piperazino)quinazoline antihypertensives | PFIZER INC. (US) | 1984-03-06 | — | — | US | disclosed |
| EP-0055583-A1 | Antihypertensives | Pfizer Limited (GB) | 1982-07-07 | — | — | EP | disclosed |
| US-3994898-A | 1,2,4-Triazolo (4,3-b) pyridazin-3-ones | E. R. SQUIBB & SONS, INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | TAAR5, CHRNA5, CHRNA4 | BPTF 3076/4885CYP1A2 1239/4885ALDH1A1 784/4885 |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | BPTF 733/4885CYP1A2 1443/4885ALDH1A1 2921/4885 |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | TAAR5, CHRNA5, CHRNA4 | BPTF 3076/4885CYP1A2 1239/4885ALDH1A1 784/4885 |
| US-20220185796-A1 | SMALL MOLECULE MODULATORS OF PANK | PANK2, PANK1, PANK3 | BPTF 3451/4885CYP1A2 4398/4885ALDH1A1 4174/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | BPTF 733/4885CYP1A2 1443/4885ALDH1A1 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.